Seroprevalence of hepatitis B virus infection among children and adolescents in Singapore, 2008-2010

被引:16
作者
Ang, Li Wei [1 ]
Tey, Su Hui [1 ]
Cutter, Jeffery [2 ]
James, Lyn [1 ]
Goh, Kee Tai [3 ]
机构
[1] Minist Hlth, Epidemiol & Dis Control Div, Singapore 169854, Singapore
[2] Minist Hlth, Communicable Dis Div, Singapore 169854, Singapore
[3] Minist Hlth, Off Director Med Serv, Singapore 169854, Singapore
关键词
hepatitis B surface antigen; antibody against hepatitis B surface antigen; national childhood immunization program; chronic hepatitis B virus infection; UNITED-STATES; IMMUNIZATION PROGRAM; VACCINE; IMMUNOGENICITY; TRANSMISSION; PREVALENCE; ENGLAND; ADULTS;
D O I
10.1002/jmv.23496
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A national pediatric survey was undertaken to determine the prevalence of hepatitis B virus markers in Singapore. The aim was to assess the impact of the national childhood immunization program against hepatitis B implemented for all newborns since 1987. The survey involved prospective collection of residual sera from Singapore residents aged 117 years attending inpatient services or day surgery in two public hospitals between August 2008 and July 2010. A total of 1,200 sera were collected comprising 400 in each of the three age groups of 16, 712, and 1317 years. The sera were tested for hepatitis B surface antigen (HBsAg) and antibody to HBsAg (anti-HBs). Four of the 1,200 samples tested positive for HBsAg, giving an overall prevalence of 0.3%. One and three in the 712 years and 1317 years age groups, respectively, were positive for HBsAg. About 40% possessed anti-HBs (10mIU/ml); the antibody prevalence decreased significantly from 63.8% in children aged 16 years to 32.8% in 712 year olds, and 23.5% in 1317 year olds (P<0.0005). The successful implementation of the national childhood hepatitis B immunization program over the last two decades has resulted in a low prevalence of HBsAg among children and adolescents. Singapore has achieved the World Health Organization Western Pacific Region's goal in reducing the prevalence of chronic HBV infection to below 2% among children aged 5 years and older by 2012 and to below 1% by 2017. J. Med. Virol. 85:583588, 2013. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:583 / 588
页数:6
相关论文
共 37 条
  • [11] The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia
    Gidding, Heather F.
    Warlow, Margaret
    MacIntyre, C. Raina
    Backhouse, Josephine
    Gilbert, Gwendolyn L.
    Quinn, Helen E.
    McIntyre, Peter B.
    [J]. VACCINE, 2007, 25 (51) : 8637 - 8641
  • [12] Goh K. T., 1997, Annals Academy of Medicine Singapore, V26, P671
  • [13] GOH KT, 1989, B WORLD HEALTH ORGAN, V67, P65
  • [14] GOH KT, 1992, B WORLD HEALTH ORGAN, V70, P233
  • [15] GOH KT, 1995, B WORLD HEALTH ORGAN, V73, P523
  • [16] Hennessey KA, 2011, TECH ADV GROUP M 9 A
  • [17] Hong WW, 2010, ANN ACAD MED SINGAP, V39, P591
  • [18] Hepatitis B Virus in the United States: Infection, Exposure, and Immunity Rates in a Nationally Representative Survey
    Ioannou, George N.
    [J]. ANNALS OF INTERNAL MEDICINE, 2011, 154 (05) : 319 - 328
  • [19] James L., 2001, SMJ Singapore Medical Journal, V42, P420
  • [20] PERSISTENCE OF SPECIFIC ANTIBODIES AFTER HEPATITIS-B VACCINATION
    JILG, W
    SCHMIDT, M
    DEINHARDT, F
    [J]. JOURNAL OF HEPATOLOGY, 1988, 6 (02) : 201 - 207